Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
New discovery on cell division could improve chemotherapies for cancer

New discovery on cell division could improve chemotherapies for cancer

EntreMed starts trial of ENMD-2076 in refractory multiple myeloma patients

EntreMed starts trial of ENMD-2076 in refractory multiple myeloma patients

Dacogen data presented on trial in seniors with acute myeloid leukemia

Dacogen data presented on trial in seniors with acute myeloid leukemia

When less is more: Brief inhibition of cancer target is effective and less toxic

When less is more: Brief inhibition of cancer target is effective and less toxic

Researchers discover why Gleevec-type drugs control, but do not eradicate leukemia

Researchers discover why Gleevec-type drugs control, but do not eradicate leukemia

Older patients with acute myloid leukemia patients show promising response in drug study

Older patients with acute myloid leukemia patients show promising response in drug study

Lenalidomide safe for elderly patients with chronic lymphocytic leukemia

Lenalidomide safe for elderly patients with chronic lymphocytic leukemia

Kiadis Pharma receives two orphan drug designations for Reviroc

Kiadis Pharma receives two orphan drug designations for Reviroc

Networks of interactive genes may predict Leukemia's development

Networks of interactive genes may predict Leukemia's development

Chronic myelogenous leukemia patient survey shows that side effects are a serious issue

Chronic myelogenous leukemia patient survey shows that side effects are a serious issue

Trial shows safety of pre-transplant expansion of umbilical cord blood stem cells

Trial shows safety of pre-transplant expansion of umbilical cord blood stem cells

New chemotherapy pill shows promise for stubborn lymphomas

New chemotherapy pill shows promise for stubborn lymphomas

Gene therapy used to fight AIDS

Gene therapy used to fight AIDS

Hematopoietic stem cells found to reproduce more slowly than expected

Hematopoietic stem cells found to reproduce more slowly than expected

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Effects of stem cell source and patient age on stem cell transplantation outcomes

Effects of stem cell source and patient age on stem cell transplantation outcomes

Age has no impact on survival after bone marrow transplant

Age has no impact on survival after bone marrow transplant

Novel therapeutic approaches for various forms of thrombocytopenia

Novel therapeutic approaches for various forms of thrombocytopenia

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Dismissed leukemia drug flavopiridol helps chronic lymphocytic leukemia patients

Dismissed leukemia drug flavopiridol helps chronic lymphocytic leukemia patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.